NASDAQ : BEAM
Beam Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 27.23 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.72B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.72B |
| Enterprise Value | 1.82B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 99.93M |
| Shares Outstanding | 99.93M |
| Shares Change (YoY) | +16.29% |
| Shares Change (QoQ) | +1.03% |
| Owned by Insiders (%) | 1.36% |
| Owned by Institutions (%) | 96.43% |
| Float | 88.33M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.44 |
| Forward PS | 54.42 |
| PB Ratio | 2.55 |
| P/TBV Ratio | 2.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 11.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.57 |
| Quick Ratio | 14.25 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -8.18% |
| Return on Assets (ROA) | -17.01% |
| Return on Invested Capital (ROIC) | -18.78% |
| Return on Capital Employed (ROCE) | -28.96% |
| Weighted Average Cost of Capital (WACC) | 14.99% |
| Revenue Per Employee | $288,954 |
| Profits Per Employee | -$160,222 |
| Employee Count | 540 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.20 |
| 52-Week Price Change | +9.93% |
| 50-Day Moving Average | 25.93 |
| 200-Day Moving Average | 28.14 |
| Relative Strength Index (RSI) | 57.69 |
| Average Volume (20 Days) | 1,937,860 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 26.24M |
| Short Previous Month | 27.55M |
| Short % of Shares Out | 26.26% |
| Short % of Float | 29.71% |
| Short Ratio (days to cover) | 13.87 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 156.04M |
| Gross Profit | -252.63M |
| Operating Income | -378.02M |
| Pretax Income | -86.52M |
| Net Income | -86.52M |
| EBITDA | -355.78M |
| EBIT | -378.02M |
| Loss Per Share | -$0.84 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 247.36M |
| Net Cash | 905.57M |
| Net Cash Per Share | $9.06 |
| Equity (Book Value) | 1.07B |
| Book Value Per Share | 10.68 |
| Working Capital | 1.10B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -359.38M |
| Capital Expenditures | -13.39M |
| Depreciation & Amortization | 22.24M |
| Net Borrowing | 93.89M |
| Free Cash Flow | -372.77M |
| FCF Per Share | -$3.73 |
Margins
| Measure | Value |
|---|
| Gross Margin | -161.91% |
| Operating Margin | -242.27% |
| Pretax Margin | -55.45% |
| Profit Margin | -55.45% |
| EBITDA Margin | -228.01% |
| EBIT Margin | -242.27% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.29% |
| Shareholder Yield | -16.29% |
| Earnings Yield | -3.08% |
| FCF Yield | -13.70% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $49.38 |
| Price Target Difference | 81.34% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | -9.74% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.08 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |